International Assets Investment Management LLC Sells 527,447 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

International Assets Investment Management LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 99.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,013 shares of the company's stock after selling 527,447 shares during the period. International Assets Investment Management LLC's holdings in IDEXX Laboratories were worth $414,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Chicago Partners Investment Group LLC boosted its stake in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after buying an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after acquiring an additional 1,453 shares during the last quarter. National Pension Service increased its position in IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after acquiring an additional 12,647 shares during the period. Insight Wealth Strategies LLC raised its holdings in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in shares of IDEXX Laboratories by 17,238.5% during the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock worth $1,139,000 after acquiring an additional 2,241 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Insiders Place Their Bets

In related news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.11% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on IDXX shares. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, November 28th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Piper Sandler reiterated a "neutral" rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays decreased their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $539.63.

IDEXX Laboratories Stock Down 3.3 %

Shares of NASDAQ:IDXX traded down $14.31 during trading on Friday, reaching $418.05. 694,879 shares of the stock were exchanged, compared to its average volume of 549,445. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market cap of $34.23 billion, a price-to-earnings ratio of 40.31, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36. The stock has a fifty day moving average of $423.76 and a two-hundred day moving average of $459.98. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $2.53 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.